Drug intelligence / Profile preview

nab-paclitaxel + phenelzine

Development stage: Unknown
Lead developer: Infinity Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of nab-paclitaxel (Abraxane), a chemotherapeutic agent, and phenelzine (Nardil), a monoamine oxidase inhibitor (MAOI) repurposed as a Lysine-Specific Demethylase-1 (LSD1) inhibitor. This combination has been studied for the treatment of metastatic breast cancer, with the rationale that LSD1 inhibition may help overcome therapeutic resistance by suppressing mesenchymal properties in cancer cells.

Targets

MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)TUBB (Tubulin (alpha and beta subunits))KDM1A (LSD1)

Beyond the preview

Go deeper on nab-paclitaxel + phenelzine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + phenelzine.

Explore the full profile